Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

IGV-001, an autologous cell immunotherapy, demonstrated an acceptable safety profile in patients with newly diagnosed glioblastoma.

IGV-001 Showcases Positive Benefit-Risk Profile in Newly Diagnosed Glioblastoma

Paolo Caimi, MD, discusses the rationale behind evaluating LMY-920, a novel BAFF CAR T-cell therapy, in relapsed/refractory non-Hodgkin lymphoma.

Dr Caimi on Early Data for LMY-920 in R/R B-Cell NHL

David H. Aggen, MD, PhD, details the evolving landscape of treating patients with urothelial carcinoma.

Navigating a “Sea Change” in Frontline Urothelial Carcinoma Treatment

Jennifer Scalici, MD, discusses data for IMNN-001plus chemotherapy in advanced ovarian cancer.

Dr Scalici on Data for IMNN-001 Plus SOC Chemotherapy in Advanced Ovarian Cancer

News

OncClub

All Oncology News

Media

Insights

MedNews Week

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

CME/CE

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Webinars

Partners

Publications

Resources

Interactive Tools

Biomarker Consortium

Subscribe


Gina Mauro is your lead editorial contact for 

. She joined the company in 2015 and has held various positions on 

; she is also the on-air correspondent for 

. Prior to joining MJH Life Sciences, she worked at Gannett as a full-time reporter with the Asbury Park Press. Email: gmauro@onclive.com 

Articles

 
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource 

. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Megan Hollasch joined MJH Life Sciences in 2022 following graduation from the University of Massachusetts Amherst with majors in Communication and English, and a specialization in Literature as History. She produces and edits original content for the print publication 

, aiding in all aspects of the publication process, as well as content for OncLive.com.

Ryan Scott joined MJH Life Sciences in 2021. In addition to writing and editing timely news and article coverage, she manages 

 social media accounts; check us out @onclive across platforms such as LinkedIn, Facebook, X, and Instagram! She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: 

Jairam Krishnamurthy, MD, FACP, details what to take into consideration when implementing 2024 Breast Cancer NCCN guideline changes into everyday practice. 

Category 1 Recommendation of Ribociclib Plus an AI Represents Huge Advancement in Breast Cancer

 in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Francisco J. Esteva, MD, PhD, highlights various pivotal studies for the treatment of HER2-positive early-stage breast cancer.

Long-Term Findings Solidify Role of HER2-Targeted Therapy in Early HER2+ Breast Cancer

Lu Chen, PhD, an Assistant Professor in the Nuclear Dynamics and Cancer Research Program has received a grant from the NIH to further investigate the role of RNA and the formation of liquid droplet structures within cancer cells.

Fox Chase Cancer Center Researcher Lu Chen Receives $250,000 NIH Grant to Further Investigation of RNA

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

Specialty

1rem

primary

View

ESMO 2024: Treatment of uHCC

Treatment Decisions Based on BLCL Stage

Video content above is prompted by the following:

What are the current treatment options, and what factors drive your treatment decision?

Atezolizumab plus bevacizumab (ImBRAVE 150 – Kudo et al. 

Durvalumab plus tremelimumab (HIMALAYA – Sangro et al. 

Videos

Panelists discuss how recent advancements in frontline and second-line therapies for unrespectable hepatocellular carcinoma (uHCC) are reshaping treatment strategies and improving patient outcomes.

Panelists discuss the current landscape of first-line treatment for unresectable hepatocellular carcinoma, highlighting key options and decision-making factors.

Current Treatment Landscape – difference between unresectable (uHCC) and metastatic (mHCC)

Panelists discuss current treatment options for unresectable hepatocellular carcinoma, including atezolizumab plus bevacizumab, durvalumab plus tremelimumab, and transarterial chemoembolization, along with the factors influencing treatment decisions.

Panelists discuss  current treatment options for unresectable hepatocellular carcinoma, including atezolizumab plus bevacizumab, durvalumab plus tremelimumab, and transarterial chemoembolization, along with the factors influencing treatment decisions.

Current Treatment in First Line –  IO + TKI or IO + IO

Panelists discuss the circumstances under which monotherapy with a tyrosine kinase inhibitor or immunotherapy would be preferred in the treatment of unresectable hepatocellular carcinoma.

Use of monotherapy (IO or TKI) or localized treatment in First Line

Panelists discuss the findings from the EMERALD-1 trial on durvalumab with or without bevacizumab combined with transarterial chemoembolization TACE for first-line treatment of unresectable hepatocellular carcinomaHCC, examining its implications on progression-free survival, safety, and outcomes based on baseline tumor burden.

EMERALD-1 Study Results

Panelists discuss  the findings from the LEAP-012 study, which explores the efficacy of transarterial chemoembolization combined with lenvatinib and pembrolizumab in patients with Child-Pugh class A disease and intermediate-stage hepatocellular carcinoma.

Discussion and Summary

Panelists discuss the results of the LEAP-012 study, highlighting the efficacy of transarterial chemoembolization combined with lenvatinib and pembrolizumab in patients with intermediate-stage hepatocellular carcinoma and Child-Pugh class A disease.

LEAP-012 Study Results

Panelists discuss  the findings from the EMERALD-1 trial on durvalumab with or without bevacizumab combined with transarterial chemoembolization TACE for first-line treatment of unresectable hepatocellular carcinomaHCC, examining its implications on progression-free survival, safety, and outcomes based on baseline tumor burden.

Discussion of LEAP-012 and EMERALD-1 Study Results and Appropriate Sequencing

Panelists discuss findings from the IMmbrave050 trial comparing atezolizumab plus bevacizumab to active surveillance in patients with high-risk hepatocellular carcinoma patients, highlighting the significance of follow-up for those at risk of recurrence post- curative treatment.

ImBRAVE 050 Study Results and Discussion Around Who is a High-Risk Patient

Panelists discuss how to determine appropriate second-line and subsequent therapies for unresectable hepatocellular carcinoma after frontline treatment, emphasizing patient-specific factors and alternatives to clinical trial enrollment.

Choosing Second-Line Therapies: Considering First Line Therapy Received

Panelists discuss the CELESTIAL trial findings and their implications for second-line treatment strategies in Japan for patients with previously treated hepatocellular carcinoma.

Discussion of CELESTIAL Trial and Second-Line Treatment in Japan

Panelists discuss the subgroup analyses from the CELESTIAL trial, focusing on treatment outcomes for specific patient populations with previously treated hepatocellular carcinoma.

CELESTIAL Sub-Group Discussion

Panelists discuss the data from the RESORCE trial, highlighting the efficacy of regorafenib in previously treated hepatocellular carcinoma, including primary trial results and insights on time to progression based on prior sorafenib treatment.

Discussion of RESORCE Trial

Panelists discuss the findings from the STELLAR trial, a phase 4 observational study presented at the European Society for Medical Oncology Congress 2024, which compares the efficacy of lenvatinib and sorafenib as first-line treatments for patients with advanced or unresectable hepatocellular carcinoma.


Treatment Decisions Based on BLCL Stage

EP: 1.Current Treatment Landscape – difference between unresectable (uHCC) and metastatic (mHCC)

EP: 2.Treatment Decisions Based on BLCL Stage

EP: 3.Current Treatment in First Line – IO + TKI or IO + IO

EP: 4.Use of monotherapy (IO or TKI) or localized treatment in First Line

EP: 5.EMERALD-1 Study Results

EP: 6.Discussion and Summary

EP: 7.LEAP-012 Study Results

EP: 8.Discussion of LEAP-012 and EMERALD-1 Study Results and Appropriate Sequencing

EP: 9.ImBRAVE 050 Study Results and Discussion Around Who is a High-Risk Patient

EP: 10.Choosing Second-Line Therapies: Considering First Line Therapy Received

EP: 11.Discussion of CELESTIAL Trial and Second-Line Treatment in Japan

EP: 12.CELESTIAL Sub-Group Discussion

EP: 13.Discussion of RESORCE Trial

EP: 14.Real-World Treatment Data from the Phase 4 STELLAR Trial

Latest Conference Coverage